Company intelligence / Profile preview
Chengdu Weisijin Biopharmaceutical Technology
Chengdu, Sichuan, Chinawestgenepharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has reached IND approval and Phase 1 for several mRNA vaccines (COVID-19, cancer, EBV), and discovery/early studies for obesity and other indications. Current clinical data is limited, with advanced programs mainly in regulatory or early clinical phase; no late-stage or NDA/marketed drugs identified.
- Therapeutic areas
- OncologyInfectious DiseasesEndocrinology
- Modalities
- mRNA vaccineTherapeutic vaccineProphylactic vaccineProteinGene editing
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Beyond the preview
Go deeper on Chengdu Weisijin Biopharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Weisijin Biopharmaceutical Technology.